The radiological intervention group is a sub-specialty group of Rimag Doctor Group divided by the specialty of the radiological intervention therapy, which focuses on the tumors, non-vascular and vascular intervention as its professional research direction, and helps Rimag Imaging Center and various medical institutions to provide interventional therapy technology training, teaching and other services.

Subject leader: Ke Xu (Chief director of Rimag Imaging Hospital, director of the Research Center for Medical Imaging Interventional Diagnosis and Treatment Technology Engineering in Liaoning Province, second-grade professor, chief physician and doctoral supervisor of the Interventional Therapy Department of First Hospital of China Medical University. former standing committee member of the Party Committee and vice principal of China Medical University, the president and director of the Radiology Department of First Hospital of China Medical University)

Expertise: Interventional treatment of tumors and vascular diseases, upper gastrointestinal hemorrhage of portal hypertension, Budd-Chiari syndrome, liver cancer, obstructive jaundice, lower limb arteriosclerosis obliterans, deep venous thrombosis and pulmonary embolism.

Expertise: Interventional treatment of tumors and vascular diseases, upper gastrointestinal hemorrhage of portal hypertension, Budd-Chiari syndrome, liver cancer, obstructive jaundice, lower limb arteriosclerosis obliterans, deep venous thrombosis and pulmonary embolism.

Social appointments: Chief executive of the Radiology Branch of the Chinese Medical Association (14th Term); the first president and tenured honorary president of the Chinese College of Interventionalists; the first to fourth chairman of the Interventional Medicine Branch of Liaoning Province; editor-in-chief of the national five-year planning textbook “Medical Imaging” for two times.

Achievements: He has been engaged in medical imaging research for a long time, focusing on the imaging diagnosis and interventional treatment of certain high-incidence and refractory diseases in China. He is the pioneer and has developed a number of new techniques, equipment and methods for interventional diagnosis and treatment in the field of Budd-Chiari syndrome, portal hypertension and peripheral vascular disease. He undertook 26 national and provincial scientific research projects, and as the project leader or chief expert, successively undertook 1 project each for the National Key Technologies R&D Program of China during the 9th Five-Year Plan Period, the National Key Technology R&D Program during the 11th Five-Year Plan Period and 863 Program during the 12th Five-Year Plan Period; and undertook 1 key program and 3 general programs of the National Natural Science Foundation of China. He published more than 400 academic papers at home and abroad, more than 130 SCI papers, and nearly 100 SCI papers as the first author. He edited or translated 9 academic monographs. He obtained 7 national patents, two of which have been transformed into clinical applications. He has won 17 provincial science and technology awards, including the second and third prizes of National Science and Technology Progress Award and the Chinese Medical Science and Technology Progress Award. He has cultivated 131 master, doctoral and postdoctoral students.